Clinical Trial Update: Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants [Phase 2]

View source ↗

Summary

Phase 2 trial update reports safety and immunogenicity of GSK's malaria vaccine 257049 administered on 7 schedules to African infants, with completed status and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Malaria vaccine 257049

Snippet

Sponsor: GlaxoSmithKline | Conditions: Malaria | Phase 2 | Status: COMPLETED | Results posted: 2015-05-20